PROSOMNUS INC (OSA)
US50535E1082 - Common Stock
OSA Stock Earnings: ProSomnus Misses EPS, Beats Revenue for Q4 2023
OSA stock results show that ProSomnus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
OSA Stock Earnings: ProSomnus Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ProSomnus (NASDAQ:OSA) just reported results for the fourth quarter of 2023.Pro...
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results...
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call ...
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea...
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices ...
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices
Additional clinical research indicates patients using ProSomnus devices have decreased apnea-hypopnea index events per hour, with strong treatment adherence
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning!
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
Record quarterly revenue of $7.1 million represents an increase of 41.5% year-over-year and seventh consecutive quarter of sequential revenue growth
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results...
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep...
ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference
ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference
PLEASANTON, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of...
ProSomnus closes $10M preferred equity round (NASDAQ:OSA)
ProSomnus (OSA) completes $10 million convertible preferred equity offering led by existing investors. Proceeds to optimize operations and fuel strategic growth.
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
Company will leverage new capital inflow to optimize core business operations, advance strategic growth initiatives, and achieve cash flow breakeven
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
Company will leverage new capital inflow to optimize core business operations, advance strategic growth initiatives, and achieve cash flow breakeven...
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
Scientific Abstracts and Presentations Feature New and Additional Data Demonstrating the Efficacy, Effectiveness, and Safety of ProSomnus Precision Devices for the Treatment of Obstructive Sleep Apnea
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
Scientific Abstracts and Presentations Feature New and Additional Data Demonstrating the Efficacy, Effectiveness, and Safety of ProSomnus Precision Devices...